Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will determine the influence of two non-caloric sweeteners on glucose metabolism via the gut microbiome in adult men and women.
This study will determine the influence of two non-caloric sweeteners on glucose metabolism via the gut microbiome in adult men and women aged 35-55 years.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sucralose | Active Comparator | Participants will be asked to consume 180 mg/day of sucralose (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 340 mg/day of sucralose (or 5.5 12-oz cans of sucralose-sweetened diet soda). |
|
| Stevia | Active Comparator | Participants will be asked to consume 180 mg/day of stevia (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 800 mg/day of stevia (or about 12 cans of stevia-sweetened diet soda). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sucralose | Other | Sweetner |
| |
| Stevia |
| Measure | Description | Time Frame |
|---|---|---|
| 2-hour glucose | An oral glucose tolerance test will be administered before and after consuming assigned sweetener to determine change in 2-hour glucose | 14 days |
| Measure | Description | Time Frame |
|---|---|---|
| Gut microbiome | Gut microbiota will be measured before and after consuming assigned sweetener to determine change in gut microbiota. | 14 days |
Not provided
Inclusion Criteria: Generally health adult men and women aged 35-55 years old -
Exclusion Criteria:Adults will not be eligible who have chronic disease (cancer, CHD, diabetes, chronic kidney disease); pregnant or breast feeding; menopausal; has a history of bariatric surgery; taking prednisone/steroids, taking medication for PCOS, or take medications that influence blood glucose.
-
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lyn M Steffen, PhD | University of Minnesota | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ECRC | Minneapolis | Minnesota | 55454 | United States |
Individual data will not be made available.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018149 | Glucose Intolerance |
| ID | Term |
|---|---|
| D006943 | Hyperglycemia |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C026285 | trichlorosucrose |
| C012043 | stevioside |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Other |
Sweetner |
|